Results 51 to 60 of about 14,945 (175)

Biologic drugs in pediatric rheumatology [PDF]

, 2016
[no ...
Al-Mayouf, Bou, Burgos-Vargas, Constantin, Haar, Horneff, Horneff, Horneff, Lachmann, Ramanan, Sen, Sen, Tarkiainen, Tarp, Watson   +14 more
core   +2 more sources

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Canakinumab [PDF]

Reactions Weekly, 2020
  +7 more sources

The development and assessment of biological treatments for children [PDF]

, 2014
The development of biological agents with specific immunological targets has revolutionized the treatment of a wide variety of paediatric diseases where traditional immunosuppressive agents have been partly ineffective or intolerable.
Akobeng, Alexeeva, Alvarez, Andborn, Anink, Baldassano, Biester, Borker, Bout-Tabaku, Braun, Brennan, Brunner, Callen, Caorsi, Cezard, Choueiter, Choy, Cleary, Colombel, Crandall, De Benedetti, De Benedetti, De Cassan, Eberhard, Eleftheriou, Feagan, Fernandes, Fleischmann, Furie, Gasparetto, Gattorno, Gerloni, Giannini, Giannini, Hanauer, Hashkes, Horneff, Horneff, Horneff, Horneff, Horneff, Horneff, Hyams, Hyams, Hyams, Irvine, Jansson, Kahn, Kanakoudi-Tsakalidou, Kaneko, Kavanaugh, Kingsbury, Kok, Kuemmerle-Deschner, Kusuhara, Kutukculer, Lehman, Lehman, Lepore, Lequerre, Lin, Lofgren, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lowite, Luu, Mangge, Mohler, Munro, Myers, Navarra, Nigrovic, Otten, Paller, Papsdorf, Podolskaya, Prince, Prince, Quartier, Quartier, Quatrier, Robinson, Rosenbach, Rosh, Rothner, Ruemmele, Runner, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Russell, Sakallioglu, Sandborn, Sandborn, Simard, Simonini, Southwood, Swart, Taylor, Toussi, Tynjala, Uperto, Vermeire, Viola, Wallace, Walters, Willems, Wyneski, Yokota, Yokota, Zannin, Zeft, Zulian   +118 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Pediatric Rheumatology Online Journal
Objective Cryopyrin-associated periodic syndrome (CAPS) is characterized by excessive IL-1β release resulting in systemic and organ inflammation. As an anti-IL-1 agent, canakinumab has been approved with all CAPS phenotypes in USA and European countries.
Xiaona Zhu, Jiaqi Fan, Yanyan Huang, Yongbin Xu, Zhi Yang, Ruohang Weng, Ying Luo, Jun Yang, Tingyan He   +8 more
doaj   +1 more source

Blockage of interleukin-1β with canakinumab in patients with Covid-19

Scientific Reports, 2020
There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19
Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo   +22 more
doaj   +1 more source

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Global & Regional Health Technology Assessment, 2020
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi   +2 more
doaj   +1 more source

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello, Luca Cantarini, Maria Cristina Maggio, Rolando Cimaz, Umberto Corpora   +4 more
core  

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source